Archive: September, 2012
A new study from the Annals of Internal Medicine says cheaper drugs would help reduce the problem of people not actually taking - or refilling - prescription medicine that would treat chronic conditions and avoid more acute and expensive problems.
The study suggested that various forms of intervention and coordination have varying results.
A link to the AIM site is here and from there you can find a link to a PDF of the study.
As Inquirer colleague Linda Loyd wrote (link here), ViroPharma plans to double its space in Exton in Chester County and create 151 new jobs, according the office of Pennsylvania Go. Tom Corbett.
ViroPharma has 188 employees now in the area.
ViroPharma received $583,000 from the Pennsylvania Department of Community and Economic Development that included a $130,000 grant and $453,000 in job-creation tax credits, according to Corbett's office.
A jury was picked and the trial was about to begin Monday morning in Philadelphia Common Pleas Court when Johnson & Johnson's Janssen Pharmaceuticals subsidiary settled a lawsuit with a Texas man who said he grew breasts as a child after being prescribed the antipsychotic drug Risperdal.
Attorneys in the case told Judge George W. Overton that the financial settlement was confidential. Plaintiff Aron Banks told the judge he agreed to the deal.
Banks, 21, declined comment afterward.
Allergan makes glaucoma drugs that are supposed to help the inside of eyes, but it is most famous for fixing the wrinkles around them with Botox.
The company actually has two Botox groups, one that makes the wrinkle products that is a cash (or credit card, more likely) business and not reimbursed by regular health-care insurers, private or public. The other makes drugs for a several parts of the body, from head to bladder, that are generally covered.
Allergan officials were in Bridgewater, N.J. last week to cut the ribbon on a new facility. Sunday's Inquirer story on what went into that choice is here.
With employment numbers making news, a smaller slice of figures emerged Thursday that reminds everybody that job destruction happens when a business buys another, whatever governments might be doing.
Though Human Genome Sciences wasn't saying anything, the Associated Press reported that HGS had notified Maryland authorities, as per law, that it was planning to lay off 114 people.
Based in Rockville, Md., HGS was acquired by GlaxoSmithKline in August after a months-long process.
Bernstein Research analyst Ronny Gal told clients that Teva leaders perhaps will invest more in developing current pharmaceutical assets, coordinate European efforts and put more emphasis in emerging markets.
Gal sent a note to clients after meeting with Teva chief executive officer Jeremy Levin and newly-appointed chief of research and development Michael Hayden at the Teva headquarters in Israel.
Levin was named CEO in January, took over in May and has publicly that he will have a grand plan in December 2012, so, as Gal noted, they were careful with specifics.
The only thing positive that Johnson & Johnson could take from Friday's decision by a three-judge panel of the Louisiana court of appeals is that a $330 million penalty wasn't increased.
As in several other state cases, J&J's Janssen Pharmaceuticals subsidiary was accused of inappropriately marketing its antipsychotic drug Risperdal through the state's Medicaid program. The Louisiana case, like those in South Carolina, Texas and Pennsylvania, were separate from consumer fraud litigation settled last week between the company and 36 states.
A Louisiana district court jury unanimously decided against Janssen.
Valeant Pharmaceuticals International, Inc., which tried very hard to buy Frazer-based Cephalon before Teva Pharmaceuticals won the bidding, Tuesday announced it would pay $2.6 billion to acquire Medicis Pharmaceutical Corp.
Valeant is based in suburban Toronto and Medicis is headquartered in Scottsdale, Ariz.
The acquisition helps give Valeant a strong position in dermatology.